You can buy Kisqali at the lowest price in the online pharmacy Nextgen.ooo . Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can cause cancer cells to grow and divide too quickly. Targeting CDK4/6 with increased precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the US FDA in March 2017.
 
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) may provide protection against oncogenic processes in certain types of tissue. For example, CDK4 is not required for normal mammary tissue development based on knockout mouse studies, but is required for the growth of Ras-induced mammary tumors, suggesting a potential therapeutic window for treatment with lower toxicity. Ribociclib has been reported to be the most selective CDK4/6 inhibitor and has dose-dependent antitumor activity in a number of preclinical models. It inhibited tumor cell growth by arresting cells at the G1 checkpoint, which prevents tumor cell proliferation.